Trial Profile
A study to evaluate long-term efficacy of Natalizumab in patients with relapsing-remitting multiple sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 20 Nov 2016 New trial record